1-propargyl-5-chloropyrimidin-2-one is a chemical compound with the molecular formula C8H5ClN2O. It is a heterocyclic compound containing a pyrimidinone ring with a propargyl group (CH2CCH) at the 1-position and a chlorine atom at the 5-position.
**Importance in Research:**
1-propargyl-5-chloropyrimidin-2-one has been investigated as a potential lead compound for the development of various drugs and therapies. Its importance in research stems from its unique structural features and potential biological activities:
* **Antiviral Activity:** The compound has shown promising antiviral activity against several viruses, including HIV and hepatitis C. Its propargyl group is known to inhibit viral enzymes and interfere with viral replication.
* **Anti-inflammatory Activity:** Studies have indicated that 1-propargyl-5-chloropyrimidin-2-one possesses anti-inflammatory properties, potentially through modulation of inflammatory pathways.
* **Anticancer Activity:** The compound has demonstrated cytotoxic effects against various cancer cell lines, suggesting its potential as an anticancer agent.
* **Drug Delivery System:** The propargyl group can be modified to attach other molecules, enabling the development of drug delivery systems for targeted drug delivery.
* **Chemical Probe:** 1-propargyl-5-chloropyrimidin-2-one can serve as a chemical probe for studying the function of enzymes and other biological targets.
**Note:**
It is important to note that research on 1-propargyl-5-chloropyrimidin-2-one is ongoing, and its clinical efficacy and safety need further investigation.
**Research Applications:**
* Development of antiviral therapies
* Discovery of anti-inflammatory drugs
* Exploration of anticancer agents
* Design of targeted drug delivery systems
* Studies of enzyme mechanisms and biological pathways
Overall, 1-propargyl-5-chloropyrimidin-2-one is a valuable research compound with potential applications in drug discovery and development. Its unique structure and biological activities make it a promising candidate for the development of new therapies for a variety of diseases.
1-propargyl-5-chloropyrimidin-2-one: mitotic inhibitor [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 124987 |
| SCHEMBL ID | 11065546 |
| MeSH ID | M0075611 |
| Synonym |
|---|
| 2(1h)-pyrimidinone, 5-chloro-1-(2-propynyl)- |
| brn 0639922 |
| 5-chloro-1-(2-propynyl)-2(1h)-pyrimidinone |
| ny 3170 |
| 1-propargyl-5-chloropyrimidin-2-one |
| ny-3170 |
| 5-chloro-1-prop-2-ynylpyrimidin-2-one |
| AKOS006275916 |
| 63331-26-0 |
| 5-24-02-00066 (beilstein handbook reference) |
| 1-propargyl-5-chloropyrimid-2-one |
| OZVGZWRCMBFDBF-UHFFFAOYSA-N |
| SCHEMBL11065546 |
| DTXSID50212717 |
| Excerpt | Reference | Relevance |
|---|---|---|
| " However, treatment with NY 3170 in combination with cis-DDP induced increased cell inactivating effects equal to a doubling of either the concentration of cis-DDP or treatment time." | ( Synergistic cell inactivation by cis-dichlorodiammineplatinum in combination with 1-propargyl-5-chloropyrimidin-2-one. Dornish, JM; Oftebro, R; Pettersen, EO, 1987) | 0.5 |
| "Inactivating effects caused by vincristine alone or in combination with another mitotic inhibitor, 1-propargyl-5-chloropyrimidin-2-one, were studied as loss of colony-forming ability in exponentially growing or synchronized populations of the human cell line NHIK 3025." | ( Age-dependent cell inactivation by vincristine alone or in combination with 1-propargyl-5-chloropyrimidin-2-one. Wibe, E, 1980) | 0.71 |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 7 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.25) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 8 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||